Bausch Health Cos (NYSE:BHC) Stock Rating Upgraded by Raymond James Financial

Bausch Health Cos (NYSE:BHC) was upgraded by investment analysts at Raymond James Financial to a “hold” rating in a report released on Monday,Zacks.com reports.

Several other research firms have also recently weighed in on BHC. Weiss Ratings restated a “hold (c-)” rating on shares of Bausch Health Cos in a research report on Monday. Wall Street Zen upgraded Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Finally, Barclays began coverage on Bausch Health Cos in a research note on Monday, December 8th. They issued an “equal weight” rating and a $8.00 price target on the stock. Five research analysts have rated the stock with a Hold rating, According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.67.

Bausch Health Cos Price Performance

BHC opened at $6.87 on Monday. The firm has a market cap of $2.55 billion, a P/E ratio of 7.11 and a beta of 0.41. The firm has a 50-day moving average of $6.49 and a 200 day moving average of $6.53. The company has a debt-to-equity ratio of 57.48, a quick ratio of 0.97 and a current ratio of 1.30. Bausch Health Cos has a fifty-two week low of $4.25 and a fifty-two week high of $8.69.

Hedge Funds Weigh In On Bausch Health Cos

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in Bausch Health Cos by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 11,746,480 shares of the company’s stock worth $76,152,000 after purchasing an additional 61,621 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Bausch Health Cos by 4.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,341,999 shares of the company’s stock worth $8,700,000 after buying an additional 57,963 shares during the last quarter. Nuveen LLC bought a new position in shares of Bausch Health Cos in the first quarter worth approximately $1,473,000. Northwest & Ethical Investments L.P. grew its holdings in shares of Bausch Health Cos by 26.3% during the first quarter. Northwest & Ethical Investments L.P. now owns 89,848 shares of the company’s stock valued at $583,000 after buying an additional 18,709 shares during the last quarter. Finally, Quantbot Technologies LP increased its position in shares of Bausch Health Cos by 387.9% during the first quarter. Quantbot Technologies LP now owns 21,235 shares of the company’s stock valued at $137,000 after acquiring an additional 16,883 shares in the last quarter. 78.65% of the stock is currently owned by institutional investors.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.